Associated Papers
A droplet digital LAMP-based lab-on-a-disc system for multiplex allele-specific detection of tumor-derived DNA mutations.
Lu H et al.
Biosensors & Bioelectronics, 2026
Analytical and clinical validation of a novel CE-IVD kit for PIK3CA hotspot mutations in liquid biopsy samples.
Stergiopoulou D et al.
The Journal of Liquid Biopsy, 2026
Genetic analysis of key players in PI3K signaling cascade of colorectal carcinoma.
Pervaiz H et al.
Scientific Reports, 2026
Clinical and Genetic Landscape of Glioblastoma, IDH-Wildtype With FGFR Gene Family Alterations.
Kegoya Y et al.
Cancer Science, 2026
PIK3CA mutation in ER-negative and HER2-positive breast cancer with apocrine differentiation.
Nozaki F et al.
Breast Cancer (tokyo, Japan), 2026
Differentiated In Vitro Efficacy of BYL719, ARQ092, and Rapamycin on Fibroblasts Isolated From a Chinese PIK3CA-Related Overgrowth Spectrum Individual With a Novel Variant.
Xiong F et al.
American Journal of Medical Genetics. Part A, 2026
Characterization of the somatic landscape and transcriptional profile of breast tumors from 748 Hispanic/Latina women in California.
Ding YC et al.
Medrxiv : the Preprint Server for Health Sciences, 2026
Coexistent PTEN and PIK3CA alterations hyperactivate mTORC1 signaling in endometrial cancers and cause their selective sensitivity to mTORC1 inhibition.
Solomon H et al.
Biorxiv : the Preprint Server for Biology, 2026
Utility of Next-Generation Sequencing in Renal Neoplasia, Including Tumors With Clear Cytoplasm and Rare Phenotypes (ELOC/MITF Alterations and Mismatch Repair Deficiency).
McCarthy M et al.
Mayo Clinic Proceedings, 2026
Pan-cancer inference and validation of hypermorphic, hypomorphic and neomorphic mutations.
Tagore S et al.
Nature Genetics, 2026
Genomic and clinicopathological characteristics of low oncotype recurrent score breast cancers with subsequent metastasis.
Liu L et al.
Histopathology, 2026
Deciphering the Genomic Landscape of Oropharyngeal Squamous Cell Carcinoma: Distinct Mutation Patterns in Disease.
Hsia B et al.
Life (basel, Switzerland), 2026
Molecular Landscape of Resected Thymomas: Insights from Mutational Profiling.
Frasca L et al.
Diagnostics (basel, Switzerland), 2026
PIK3CA Alterations in NSCLC: Clinical Characteristics of a "Neglected" Population of Oncogene-Addicted Patients.
Rossi S et al.
Biomedicines, 2026
Genomic Profiling of Pediatric Solid Tumors With a Dual DNA/RNA Panel: JCCG-TOP2 Study.
Tao K et al.
Cancer Science, 2026
Clinical Significance of Molecular Genetic Analysis in Diffuse Intrinsic Pontine Glioma: Two Case Reports.
Inamine I et al.
Pediatric Blood & Cancer, 2026
Genomic landscape of metastatic breast cancers in young adults: a liquid biopsy analysis of women aged 20-40 years.
Diab E et al.
Breast (edinburgh, Scotland), 2026
Identifying and capitalizing on unique molecular alterations of mucinous ovarian carcinoma for the development of novel therapeutic strategies.
Jang M et al.
Gynecologic Oncology Reports, 2026
Alpelisib, a PI3Kα inhibitor, effectively treats vascular anomalies with diverse genotypes and phenotypes.
Pithadia DJ et al.
Blood Vessels, Thrombosis & Hemostasis, 2026
Detection of Cancer-Associated Mutations Using Primer Exchange Reaction-Based Signal Amplification and Lateral Flow Assays.
Kocabey S et al.
Small Science, 2026
Next-Generation Sequencing-Based Detection of KRAS G12D Variants in Colorectal Cancer: A Retrospective Cohort Study.
Hekimoglu G et al.
Genes, 2026
PIK3CA Mutations Downregulate PPT1 to Promote Adipogenesis by Suppressing P300 Depalmitoylation and Phase Separation.
Chen H et al.
Advanced Science (weinheim, Baden-wurttemberg, Germany), 2026
Common gene mutations in 103 authenticated colorectal cancer cell lines.
Kranjec C et al.
Oncogenesis, 2026
Integrated genomic and proteomic profiling reveals insights into chemoradiation resistance in cervical cancer.
Sambath J et al.
Molecular Oncology, 2026
Molecular Characterization of Vascular Anomalies Tissues Guides Clinical Diagnosis.
Henslee SB et al.
Lymphatic Research and Biology, 2026
A new functional assay reveals that membrane binding is critical for overactivation of the phosphoinositide 3-kinase H1047R mutant.
Papafotika A et al.
The Journal of Biological Chemistry, 2026
A Three-subtype Molecular model of Cervical Cancer: Multiple PI3K Pathway inhibitors suppress growth and cooperate with HPV-directed immunotherapy.
Lou H et al.
Medrxiv : the Preprint Server for Health Sciences, 2026
Genomic evolution of pancreatic cancer at single-cell resolution.
Zhang H et al.
Nature Genetics, 2026
Oncogenic PI3Kα variants reveal graded conformational spectrum with mutation-specific cryptic pockets.
Jang H et al.
Communications Chemistry, 2026
Angiogenic switching in cerebral cavernous malformations driven by MAP3K3-PIK3CA synergy.
Ren J et al.
Brain : a Journal of Neurology, 2026
"Beyond HER2 overexpression: somatic alterations in HER2 and PI3K genes in HER2-high and HER2-low/TNBC breast cancer.
Thakur T et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2026
Targeting the Uncommon: A Case Report of Osimertinib Response in Advanced NSCLC Patient with Dual EGFR (E701fs and L702fs) Frameshift Deletions.
Wong AKQ et al.
Current Oncology (toronto, Ont.), 2026
Association of TIGIT and CD155 with KRAS, NRAS, BRAF, PIK3CA, and AKT Gene Mutations, MSI Status, and Cytokine Profiles in Colorectal Cancer.
Ochman B et al.
International Journal of Molecular Sciences, 2026
Small Nucleotide Variant Analysis Using RNA Fusion Panel (SMURF): Making the Most of RNAseq Data in Solid Tumours.
Dorwal P et al.
Journal of Clinical Laboratory Analysis, 2026
EML4-ALK Variant-Specific Genetic Interactions Shape Lung Tumorigenesis.
Diaz-Jimenez A et al.
Cancer Discovery, 2026
Systematic evaluation of neoepitope predictions challenges clinically observed T-cell responses and their impact on immune evasion.
Zaghla BKQ et al.
Journal for Immunotherapy of Cancer, 2026
Comprehensive Genomic Characterization of 102 Cervical Adenocarcinoma Tumors.
Toromani G et al.
Medicina (kaunas, Lithuania), 2026
PI3Kα Inhibitor and Degrader Inavolisib Can Co-opt FGFR2 to Enhance Responses in Patients with PIK3CA-Mutated Solid Tumors and in Preclinical Models.
Juric D et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2026
Clinical and Genomic Factors Associated with Elacestrant Outcomes in ESR1-Mutant Metastatic Breast Cancer.
Lloyd MR et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2026
PRIME: an interpretable artificial intelligence model based on liquid biopsy improves prediction of progression risk in non-small cell lung cancer.
Wang Y et al.
Military Medical Research, 2026
Decoding the Mutational Hierarchy of Thyroid Cancer and Associated Signaling Pathways.
Nashier D et al.
Archives of Medical Research, 2026
Clinical utility of longitudinal circulating tumor DNA analysis in metastatic colorectal cancer patients receiving palliative chemotherapy.
Oh CR et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2026
Binimetinib and encorafenib for the treatment of advanced solid tumors with non-V600E BRAF mutations: results from the Phase II BEAVER trial.
Rose AAN et al.
Nature Communications, 2026
Structural Insights into the Development of Inhibitors Against Cancer-Specific Mutations of PI3Kα.
Liu X et al.
Annual Review of Pharmacology and Toxicology, 2026
From PIK3CA Mutations to Rational PI3K Inhibition for the Treatment of Colorectal Cancer.
Voutsadakis IA
Molecular Diagnosis & Therapy, 2026